Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.

Passiglia, Francesco; Galvano, Antonio; Rizzo, Sergio; Incorvaia, Lorena; Listì, Angela; Bazan, Viviana; Russo, Antonio

Passiglia, Francesco; Galvano, Antonio; Rizzo, Sergio; Incorvaia, Lorena; Listì, Angela; Bazan, Viviana; Russo, Antonio.

Afiliación

Passiglia F; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy.
Galvano A; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy.
Rizzo S; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy.
Incorvaia L; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy.
Listì A; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy.
Bazan V; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy.
Russo A; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, Palermo University Hospital, Palermo, Italy.

Int J Cancer ; 142(6): 1277-1284, 2018 03 15.

Article en En | MEDLINE | ID: mdl-29080213

Asunto(s)

Antineoplásicos/uso terapéutico; Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico; Receptores Coestimuladores e Inhibidores de Linfocitos T/antagonistas & inhibidores; Neoplasias Pulmonares/tratamiento farmacológico; Anticuerpos Monoclonales/uso terapéutico; Anticuerpos Monoclonales Humanizados/uso terapéutico; Carcinoma de Pulmón de Células no Pequeñas/mortalidad; Ensayos Clínicos Fase II como Asunto; Ensayos Clínicos Fase III como Asunto; Docetaxel; Humanos; Incidencia; Neoplasias Pulmonares/mortalidad; Nivolumab; Neumonía/inducido químicamente; Neumonía/epidemiología; Ensayos Clínicos Controlados Aleatorios como Asunto; Análisis de Supervivencia; Taxoides/uso terapéutico; Resultado del Tratamiento

Palabras clave

NSCLC; PD1; PDL1; atezolizumab; immune-checkpoint; nivolumab; pembrolizumab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / Receptores Coestimuladores e Inhibidores de Linfocitos T / Neoplasias Pulmonares / Antineoplásicos Tipo de estudio: Clinical_trials / Etiology_studies / Incidence_studies / Prognostic_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Int J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google